In Cameroon, due to the implementation of the Test and Treat policy in 2016, antiretroviral therapy (ART) was generalized to all people affected by HIV. In people living with HIV (PLHIV) born HIV positive, although this treatment controls the plasma viral load of HIV, they are even more at risk of comorbidities compared to the general population. In addition, high levels of immune activation and inflammation persist despite control of HIV viremia, and associated to morbidities not ranking AIDS and the reactivation of other chronic viral infections, define a decline of the immune system called immunosenescence. Immunosenescence is appeared early in PLHIV born HIV positive but their follow-up is no different from those who acquired the infection late in life, leading to their early death unrelated to HIV infection. The general objective of this work was to identify biomarkers that could be included in the monitoring of PLHIV born HIV positive in order to predict the occurrence of immunosenescence. Between 2020 and 2022, we conducted a monocentric prospective study at Yaoundé on PLHIV born HIV positive from whom the socio-demographic profile was established. Biological parameters were measured in blood from two sampling periods (at recruitment and 12 months later), for the purpose of measure immune activation, inflammatory profile and markers of organ aging in order to bring out the combination of markers found relevant for the study of the immunosenescence of participants. It appears that, of the 20 biomarkers LTCD4+, LTCD8+, CD4/CD8 ratio, Platelets, Leukocytes, Monocytes, Neutrophils, Total leukocytes, Hemoglobin, TNF-α, IFN-γ, IL-2, IL-6, Creatinine, urea, AST, ALT, ALT/AST ratio, comorbidities, coinfections) described in the literature as being able to monitor immunosenescence, only 5 (LTCD4+, total leukocytes, platelets, IL-2 and IFN-γ) were found relevant to describe this state in our participants, parameters that can be measured with routine examinations (NFS, ELISA).